Join Bell Financial Group's Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company's lead drug candidate ARG-007, and its pathway to commercialisation to become the world's first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury.
In this interview, Liz covers:
• (0:40) an overview of Argenica Therapeutics (ASX:AGN)
• (1:28) details on ARG-007, including its mechanism in protecting brain cells after stroke
• (4:59) expected runway, and potential need for additional financing pre-Phase 3
• (8:42) other drug candidates in development within Argenica’s pipeline
• (10:01) expected investor news flow over the next 12 months
Note: This interview was filmed on 24 September 2025.
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.